Cargando…

RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing

AKT-phosphorylated IWS1 regulates alternative RNA splicing via a pathway that is active in lung cancer. RNA-seq studies in lung adenocarcinoma cells lacking phosphorylated IWS1, identified a exon 2-deficient U2AF2 splice variant. Here, we show that exon 2 inclusion in the U2AF2 mRNA is a cell cycle-...

Descripción completa

Detalles Bibliográficos
Autores principales: Laliotis, Georgios I., Chavdoula, Evangelia, Paraskevopoulou, Maria D., Kaba, Abdul, La Ferlita, Alessandro, Singh, Satishkumar, Anastas, Vollter, Nair, Keith A., Orlacchio, Arturo, Taraslia, Vasiliki, Vlachos, Ioannis, Capece, Marina, Hatzigeorgiou, Artemis, Palmieri, Dario, Tsatsanis, Christos, Alaimo, Salvatore, Sehgal, Lalit, Carbone, David P., Coppola, Vincenzo, Tsichlis, Philip N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324843/
https://www.ncbi.nlm.nih.gov/pubmed/34330897
http://dx.doi.org/10.1038/s41467-021-24795-1
Descripción
Sumario:AKT-phosphorylated IWS1 regulates alternative RNA splicing via a pathway that is active in lung cancer. RNA-seq studies in lung adenocarcinoma cells lacking phosphorylated IWS1, identified a exon 2-deficient U2AF2 splice variant. Here, we show that exon 2 inclusion in the U2AF2 mRNA is a cell cycle-dependent process that is regulated by LEDGF/SRSF1 splicing complexes, whose assembly is controlled by the IWS1 phosphorylation-dependent deposition of histone H3K36me3 marks in the body of target genes. The exon 2-deficient U2AF2 mRNA encodes a Serine-Arginine-Rich (RS) domain-deficient U2AF65, which is defective in CDCA5 pre-mRNA processing. This results in downregulation of the CDCA5-encoded protein Sororin, a phosphorylation target and regulator of ERK, G2/M arrest and impaired cell proliferation and tumor growth. Analysis of human lung adenocarcinomas, confirmed activation of the pathway in EGFR-mutant tumors and showed that pathway activity correlates with tumor stage, histologic grade, metastasis, relapse after treatment, and poor prognosis.